PRPH

ProPhase Labs Inc. (PRPH) | Rumor.io

ProPhase Labs

PRPH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio13.6

Market capitalization1.1M

Earnings per share-1.85

Dividend yield (TTM)15.8K%

Revenue (annual)4.3M

Net income (annual)-14.7M

Social

What share of all stock conversation is about PRPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jan 22

ProPhase Labs ($PRPH) has been approved to uplist to the OTC Market from the Pink Sheets.
The company expects to share a positive operational update soon, citing encouraging momentum in its Crown Medical collections initiative.
ProPhase Labs has a market capitalization of under $2 million and approximately 9.5 million shares outstanding.

Generated by AI

Sentiment

Of the messages about PRPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	77.47% -6.57
Bearish	—	—	0%	22.53% +6.57

Bullish· Dec 23

$PRPH is considered a bargain at its current price due to recent relative strength, low float, and potential merger.
A positive public relations campaign could send $PRPH higher, and the stock has not yet crashed despite recent volatility.
Large European buyers are expected to buy up the entire float of $PRPH, driving the price up and potentially back above $1.

Bearish· Jan 2

$PRPH is being delisted from NASDAQ due to failure to meet bid requirements, and will be trading on the OTC.
The company's delisting is expected to lead to a significant decline in price, potentially reaching as low as $0.01 or lower.
The CEO's performance has been criticized, and some investors are expressing regret for not selling earlier, with one post suggesting that the stock is a "scam" and others warning of a potential price drop to $0.10.

Generated by AI

Topics

Of the messages about PRPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	37.31%
Announcements	—	—	0%	4.19%
Controversies	—	—	0%	0.13%
Earnings	—	—	100%	0.1%
Macro	—	—	0%	37.29%
Technical Analysis	—	—	0%	20.98%

Announcements· Dec 19

ProPhase Labs ($PRPH) has signed a non-binding letter of intent with Advanced Biological Laboratories (ABL) for a reverse merger, which may bring cutting-edge diagnostic technology and liver function technology.
The proposed merger could result in a special cash dividend of up to $10 million for $PRPH shareholders and an additional $50 million in collections.
ProPhase Labs may declare a special cash dividend of up to $10 million payable to shareholders of ProPhase Labs common stock as part of the proposed reverse merger with Advanced Biological Laboratories.

Technical Analysis· Dec 19

$PRPH is expected to make another run, with high volume buying candles and a potential breakout above $0.33.
The stock has formed a descending wedge and is breaking VWAP, with increasing volume, indicating a possible continuation of the trend.
Technical analysis suggests that $PRPH is experiencing bearish pressure, with a severe downtrend and oversold conditions, but is approaching a potential breakout above $0.10.

Generated by AI

Community

Of the messages about PRPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	51.11%	15.07%
Newcomers	—	0%	48.89%	84.93%

Regulars· Dec 19

ProPhase Labs has signed a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories, which could lead to a special cash dividend of up to $10 million for current shareholders.
The reverse merger could also result in additional carveouts for ProPhase Labs, including a potential $50 million in collections.
ProPhase Labs has retained new legal counsel and is submitting a replacement opinion of counsel, which supersedes the previous opinion filed on October 15, 2025.

Newcomers· Dec 19

The company ProPhase Labs has signed a non-binding letter of intent with European biotechnology giant Advanced Biological Laboratories (ABL) for a reverse merger, which could bring cutting-edge diagnostic technology.
The stock has seen significant price movement, with a target price of $16 and an upside potential of ~9900% from its current price of ~$0.16.
The company's diluted shares have increased, with a potential 1-for-10 split, and some investors are speculating about a possible recovery or a rebound in the stock's price.

Generated by AI

Also Discussed

Investors talking about PRPH also mention

#	Name	Attention
1	VIVK - Vivakor, Inc.	——
2	Erayak Power Solution Group Inc. Class A Ordinary SharesRAYA	0%0
3	AtlasClear Holdings, Inc.ATCH	0.01%0
4	IVP - Inspire Veterinary Partners, Inc.	——
5	Healthcare Triangle Inc.HCTI	0%0
6	Dragonfly Energy Holdings Corp.DFLI	0%0
7	Cycurion Inc.CYCU	0%0
8	Aspire Biopharma Holdings, Inc.ASBP	0%new
9	Processa Pharmaceuticals Inc.PCSA	0%0
10	Mingteng International Corporation Inc.MTEN	0%0

ProPhase Labs Inc.

Healthcare
Diagnostics & Research

ProPhase Labs Inc. is a diversified health sciences company engaged in various segments of healthcare and diagnostics. The primary function of ProPhase Labs is to develop, manufacture, and market an array of over-the-counter (OTC) consumer healthcare products. The company has a crucial role in the health and wellness sector by providing innovative solutions for common ailments. Notably, ProPhase Labs also operates within the genetic testing and diagnostics space, offering services that cater to growing demands for personalized medicine and preventive healthcare measures. With a significant presence in both consumer products and advanced diagnostic services, ProPhase Labs impacts sectors ranging from retail healthcare to biotechnology. As a company continually expanding its product lines and diagnostic capabilities, ProPhase Labs positions itself as an integral player in fostering accessible health solutions, thereby enhancing its market significance in the dynamic landscape of healthcare innovation and delivery.

Website

Location

626 RXR Plaz

Uniondale, NY, 11556

United States

Social

What share of all stock conversation is about PRPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jan 22

ProPhase Labs ($PRPH) has been approved to uplist to the OTC Market from the Pink Sheets.
The company expects to share a positive operational update soon, citing encouraging momentum in its Crown Medical collections initiative.
ProPhase Labs has a market capitalization of under $2 million and approximately 9.5 million shares outstanding.

Generated by AI

Sentiment

Of the messages about PRPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	77.47% -6.57
Bearish	—	—	0%	22.53% +6.57

Bullish· Dec 23

$PRPH is considered a bargain at its current price due to recent relative strength, low float, and potential merger.
A positive public relations campaign could send $PRPH higher, and the stock has not yet crashed despite recent volatility.
Large European buyers are expected to buy up the entire float of $PRPH, driving the price up and potentially back above $1.

Bearish· Jan 2

$PRPH is being delisted from NASDAQ due to failure to meet bid requirements, and will be trading on the OTC.
The company's delisting is expected to lead to a significant decline in price, potentially reaching as low as $0.01 or lower.
The CEO's performance has been criticized, and some investors are expressing regret for not selling earlier, with one post suggesting that the stock is a "scam" and others warning of a potential price drop to $0.10.

Generated by AI

Topics

Of the messages about PRPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	37.31%
Announcements	—	—	0%	4.19%
Controversies	—	—	0%	0.13%
Earnings	—	—	100%	0.1%
Macro	—	—	0%	37.29%
Technical Analysis	—	—	0%	20.98%

Announcements· Dec 19

ProPhase Labs ($PRPH) has signed a non-binding letter of intent with Advanced Biological Laboratories (ABL) for a reverse merger, which may bring cutting-edge diagnostic technology and liver function technology.
The proposed merger could result in a special cash dividend of up to $10 million for $PRPH shareholders and an additional $50 million in collections.
ProPhase Labs may declare a special cash dividend of up to $10 million payable to shareholders of ProPhase Labs common stock as part of the proposed reverse merger with Advanced Biological Laboratories.

Technical Analysis· Dec 19

$PRPH is expected to make another run, with high volume buying candles and a potential breakout above $0.33.
The stock has formed a descending wedge and is breaking VWAP, with increasing volume, indicating a possible continuation of the trend.
Technical analysis suggests that $PRPH is experiencing bearish pressure, with a severe downtrend and oversold conditions, but is approaching a potential breakout above $0.10.

Generated by AI

Community

Of the messages about PRPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	51.11%	15.07%
Newcomers	—	0%	48.89%	84.93%

Regulars· Dec 19

ProPhase Labs has signed a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories, which could lead to a special cash dividend of up to $10 million for current shareholders.
The reverse merger could also result in additional carveouts for ProPhase Labs, including a potential $50 million in collections.
ProPhase Labs has retained new legal counsel and is submitting a replacement opinion of counsel, which supersedes the previous opinion filed on October 15, 2025.

Newcomers· Dec 19

The company ProPhase Labs has signed a non-binding letter of intent with European biotechnology giant Advanced Biological Laboratories (ABL) for a reverse merger, which could bring cutting-edge diagnostic technology.
The stock has seen significant price movement, with a target price of $16 and an upside potential of ~9900% from its current price of ~$0.16.
The company's diluted shares have increased, with a potential 1-for-10 split, and some investors are speculating about a possible recovery or a rebound in the stock's price.

Generated by AI

ProPhase Labs

Social

Jan 22

Sentiment

Bullish· Dec 23

Bearish· Jan 2

Topics

Announcements· Dec 19

Technical Analysis· Dec 19

Community

Regulars· Dec 19

Newcomers· Dec 19

Also Discussed

ProPhase Labs Inc.

Company Information

Location

Also Discussed

Social

Jan 22

Sentiment

Bullish· Dec 23

Bearish· Jan 2

Topics

Announcements· Dec 19

Technical Analysis· Dec 19

Community

Regulars· Dec 19

Newcomers· Dec 19